Orphan Drug Status for RPI-78M Boosts Nutra Pharma Corp.’s (NPHC) IP Portfolio
Last September’s award of orphan drug status to Nutra Pharma Corporation (OTCQB: NPHC) for RPI-78M for the treatment of Juvenile or Pediatric Multiple Sclerosis was a significant milestone on the company’s road to success as a speculative bio-pharmaceutical company. In an interview (http://dtn.fm/7jXjw) with Stock News Now, CEO Rik Deitsch called the award “the most substantial event in the history of our drug discovery efforts,” but went on to lament that, ironically, the company had been hobbled by its own success. Although essentially focused on drug discovery, Nutra Pharma markets an over-the-counter (OTC) line of homeopathic remedies. This includes Cobroxin,…